(A) Lollipop plots depicting the identified point mutations in NTRK2 (upper panel) and NTRK3 (lower panel) genes. Bold black marks indicate experimentally validated oncogenicity of the mutation; gray marks indicate failure to demonstrate oncogenicity. The diseases of patients in which the point mutations were identified are indicated in dark red. (B) Proposed mechanism by which the identified NTRK mutations increase oncogenicity. AML, acute myeloid leukemia; CML, chronic myeloid leukemia; MF, myelofibrosis; T-ALL, T-cell acute lymphoblastic leukemia.